Sunrise in melanoma management: Time to focus on melanoma burden in Asia.

about

Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

P2860

Q48507831-771D68BB-D6E1-4429-9210-38A754B8E351

P2860

Sunrise in melanoma management: Time to focus on melanoma burden in Asia.

Item

http://www.wikidata.org/entity/Q36280711

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Sunrise in melanoma management: Time to focus on melanoma burden in Asia.

@ast

Sunrise in melanoma management: Time to focus on melanoma burden in Asia.

@en

type

Item

label

Sunrise in melanoma management: Time to focus on melanoma burden in Asia.

@ast

Sunrise in melanoma management: Time to focus on melanoma burden in Asia.

@en

prefLabel

Sunrise in melanoma management: Time to focus on melanoma burden in Asia.

@ast

Sunrise in melanoma management: Time to focus on melanoma burden in Asia.

@en

P1476

Sunrise in melanoma management: Time to focus on melanoma burden in Asia.

@en

P2093

Anthony Ying

http://www.w3.org/2001/XMLSchema#string

Boman Dhabhar

http://www.w3.org/2001/XMLSchema#string

Chia-Yen Hung

http://www.w3.org/2001/XMLSchema#string

Gwo Fuang Ho

http://www.w3.org/2001/XMLSchema#string

Huu Sau Nguyen

http://www.w3.org/2001/XMLSchema#string

John Wen-Cheng Chang

http://www.w3.org/2001/XMLSchema#string

Jun Guo

http://www.w3.org/2001/XMLSchema#string

Maria Luisa Tiambeng

http://www.w3.org/2001/XMLSchema#string

Naoya Yamazaki

http://www.w3.org/2001/XMLSchema#string

Nugroho Prayogo

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Nivolumab in previously untreated melanoma without BRAF mutation

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study.

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.

P31

scholarly article

P356

10.1111/AJCO.12670

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28198155

http://www.w3.org/2001/XMLSchema#string

Sunrise in melanoma management: Time to focus on melanoma burden in Asia.

about

P2860

P2860

Sunrise in melanoma management: Time to focus on melanoma burden in Asia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698